Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michaela Diamant

Showing results (161-170 of 212) with videos related to

Pageof 22
Sort By:
Metabolism: Clinical and Experimental|November 21, 2012
Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance?Daniël H van Raalte, Kelly A A Kwa, Renate E van Genugten, et al.
Diabetes Care|October 4, 2012
Prospective associations of B-type natriuretic peptide with markers of left ventricular function in individuals with and without type 2 diabetes: an 8-year follow-up of the Hoorn StudyMaria H Kroon, Katja van den Hurk, Marjan Alssema, et al.
Diabetes Care|February 7, 2009
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trialMathijs C Bunck, Michaela Diamant, Anja Cornér, et al.
Diabetes Care|September 3, 2016
Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled TrialLennart Tonneijck, Mark M Smits, Marcel H A Muskiet, et al.
Plos One|July 7, 2012
Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trialGijs H Goossens, Chantalle C M Moors, Nynke J van der Zijl, et al.
Biochimica Et Biophysica Acta|December 23, 2006
Functioning of oxidative phosphorylation in liver mitochondria of high-fat diet fed ratsJolita Ciapaite, Stephan J L Bakker, Gerco Van Eikenhorst, et al.
Diabetes Technology & Therapeutics|October 28, 2014
A decision support tool for appropriate glucose-lowering therapy in patients with type 2 diabetesF Javier Ampudia-Blasco, Pierre Yves Benhamou, Guillaume Charpentier, et al.
Cellular Signalling|May 29, 2013
Proline-rich Akt substrate of 40-kDa contains a nuclear export signalClaudia Wiza, Emmani B M Nascimento, Margot M L Linssen, et al.
Diabetologia|September 20, 2015
Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetesJennifer S ten Kulve, Dick J Veltman, Liselotte van Bloemendaal, et al.
Diabetes Care|January 25, 2019
Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050Lennart Tonneijck, Mark M Smits, Marcel H A Muskiet, et al.
Pageof 22

Showing results (161-170 of 212) with videos related to

Sort By:
Pageof 22
Metabolism: Clinical and Experimental|November 21, 2012
Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance?Daniël H van Raalte, Kelly A A Kwa, Renate E van Genugten, et al.
Diabetes Care|October 4, 2012
Prospective associations of B-type natriuretic peptide with markers of left ventricular function in individuals with and without type 2 diabetes: an 8-year follow-up of the Hoorn StudyMaria H Kroon, Katja van den Hurk, Marjan Alssema, et al.
Diabetes Care|February 7, 2009
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trialMathijs C Bunck, Michaela Diamant, Anja Cornér, et al.
Diabetes Care|September 3, 2016
Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled TrialLennart Tonneijck, Mark M Smits, Marcel H A Muskiet, et al.
Plos One|July 7, 2012
Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trialGijs H Goossens, Chantalle C M Moors, Nynke J van der Zijl, et al.
Biochimica Et Biophysica Acta|December 23, 2006
Functioning of oxidative phosphorylation in liver mitochondria of high-fat diet fed ratsJolita Ciapaite, Stephan J L Bakker, Gerco Van Eikenhorst, et al.
Diabetes Technology & Therapeutics|October 28, 2014
A decision support tool for appropriate glucose-lowering therapy in patients with type 2 diabetesF Javier Ampudia-Blasco, Pierre Yves Benhamou, Guillaume Charpentier, et al.
Cellular Signalling|May 29, 2013
Proline-rich Akt substrate of 40-kDa contains a nuclear export signalClaudia Wiza, Emmani B M Nascimento, Margot M L Linssen, et al.
Diabetologia|September 20, 2015
Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetesJennifer S ten Kulve, Dick J Veltman, Liselotte van Bloemendaal, et al.
Diabetes Care|January 25, 2019
Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050Lennart Tonneijck, Mark M Smits, Marcel H A Muskiet, et al.
Pageof 22